Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 7/20 | 0.49 |
| ▸ | ATP4B known ✓ | P51164 | 7/20 | 0.49 |
| ▸ | BRS3 | P32247 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.49 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.49 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.49 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.49 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.49 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.49 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.49 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.49 |
| ▸ | WDR5 | P61964 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.49 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL144577 | 1.00 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL28300201 | 1.00 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL589807 | 1.00 | BRS3 (0.51) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL2484203 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL1713666 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL6829013 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL4371701 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL142905 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Esomeprazole SCHEMBL29002845 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 | |
| Omeprazole SCHEMBL28754295 | 0.99 | BRS3 (0.50) | BRS3ATP4AATP4BKMT2AATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889873-B2 | Process for the preparation of enantiomerically enriched proton pump inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2014-11-18 | — | — | US | disclosed |
| US-8362259-B2 | Process for the preparation of esomeprazole magnesium in a stable form | LEK PHARMACEUTICALS, D.D. (SI) | 2013-01-29 | — | — | US | disclosed |
| EP-2114918-B1 | PROCESS FOR SOLVENT REMOVAL FROM OMEPRAZOLE SALTS | LEK PHARMACEUTICALS (SI) | 2012-10-03 | — | — | EP | disclosed |
| US-8247567-B2 | Process for solvent removal from omeprazole salts | LEK PHARMACEUTICALS, D.D. (SI) | 2012-08-21 | — | — | US | disclosed |
| US-20120046319-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS | LEK PHARMACEUTICALS D.D. (SI) | 2012-02-23 | — | — | US | disclosed |
| US-20110212090-A1 | Combinatorial Analysis and Repair | DAKO DENMARK A/S | 2011-09-01 | — | — | US | disclosed |
| US-7875723-B2 | 99.9% By weight of amorphous S-omeprazole magnesium, <0.1% by weight of impurities as determined by liquid chromatography; X-ray powder diffractogram; substantially free of neutral omeprazole; optical purity 94-96% e.e.; anhydrous; industrial scale; materials handling; filterable | LEK PHARMACEUTICALS D.D. (SL) | 2011-01-25 | — | — | US | disclosed |
| EP-2264024-A1 | Process for the preparation of enantiomerically enriched proton pump inhibitors | LEK Pharmaceuticals d.d. (SI) | 2010-12-22 | — | — | EP | disclosed |
| US-20100087652-A1 | S-Omeprazole Magnesium | LEK PHARMACEUTICALS D.D. (SI) | 2010-04-08 | — | — | US | disclosed |
| EP-2147918-A1 | Process for the preparation of S-omeprazole magnesium in a stable form | LEK Pharmaceuticals D.D. (SI) | 2010-01-27 | — | — | EP | disclosed |
| US-20100016370-A1 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM IN A STABLE FORM | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | US | disclosed |
| US-7553857-B2 | 99.9% By weight of amorphous S-omeprazole magnesium, <0.1% by weight of impurities as determined by liquid chromatography; X-ray powder diffractogram; substantially free of neutral omeprazole; optical purity 94-96% e.e.; anhydrous; industrial scale; materials handling; filterable | LEK PHARMACEUTICALS D.D. (SI) | 2009-06-30 | — | — | US | disclosed |
| EP-1947099-A1 | Process for solvent removal from omeprazole salts | LEK Pharmaceuticals D.D. (SI) | 2008-07-23 | — | — | EP | disclosed |
| US-4738974-A | Base addition salts of omeprazole | AKTIEBOLAGET HASSLE (SE) | 1988-04-19 | — | — | US | disclosed |
| EP-0124495-B1 | OMEPRAZOLE SALTS | Aktiebolaget Hässle (SE) | 1987-01-14 | — | — | EP | disclosed |
| EP-0124495-A2 | Omeprazole salts | Aktiebolaget Hässle (SE) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016370-A1 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM IN A STABLE FORM | RPS27A, ATP6AP1, RPS26 | ATP4A 423/4885ATP4B 411/4885BRS3 2623/4885 |
| US-20120046319-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED PROTON PUMP INHIBITORS | PPOX, HPD, HRH2 | ATP4A 100/4885ATP4B 46/4885BRS3 992/4885 |
| US-20100087652-A1 | S-Omeprazole Magnesium | RPS4X, ELL, RPL41 | ATP4A 93/4885ATP4B 127/4885BRS3 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.